Pharma TechReposted from WuXi STAWe appreciate the “Platinum Service Awards” from Teon Therapeutics to recognize WuXi STA’s outstanding contribution to their drug product…Jun 27, 2023Jun 27, 2023
Pharma TechReposted from WuXi STAFacility Spotlight: Recently, we opened another large-scale API plant with 277 m3 total reactor volume in our Changzhou, China site. The…Jun 27, 2023Jun 27, 2023
Pharma TechReposted from WuXi STAWhat are the most significant issues shaping the pharma customer-supplier relationship in 2022? Dr. Xiaoyong Fu, Chief Technology Officer…Jun 27, 2023Jun 27, 2023
Pharma TechReposted from WuXi STARecently we completed the expansion of the enzyme fermentation plant as part of our biocatalysis platform in our Shanghai Jinshan site by…Jun 27, 2023Jun 27, 2023
Pharma TechReposted from WuXi STAOur Shanghai Waigqaoqiao site successfully passed its first drug product pre-approval inspection (PAI) by the US FDA. It is another…Jun 27, 2023Jun 27, 2023
Pharma TechReposted from WuXi STATechnology spotlight: WuXi STA’s flow chemistry platform continually expands. We recently launched 4 additional flow manufacturing lines…Jun 27, 2023Jun 27, 2023
Pharma TechReposted from WuXi STAWe appreciate the “Platinum Service Awards” from Teon Therapeutics to recognize WuXi STA’s outstanding contribution to their drug product…Jun 27, 2023Jun 27, 2023
Pharma TechWuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet…State-of-the-art facility significantly enhances WuXi STA’s drug product capacity in Europe while better enabling global customersJun 27, 2023Jun 27, 2023
Pharma TechWuXi STA Opens Another High-Potency API Plant in Changzhou, ChinaShanghai, China — June 24, 2022 — WuXi STA, a WuXi AppTec company, has opened another high-potency API (HPAPI) plant at its Changzhou site…Jun 27, 2023Jun 27, 2023
Pharma TechWuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing FacilitySite Enhances New Modality CRDMO Platform Capacity for CustomersJun 27, 2023Jun 27, 2023